Mutational landscape of chronic myeloid leukemia : more than a single oncogene leukemia

Show full item record



Permalink

http://hdl.handle.net/10138/340395

Citation

Adnan-Awad , S , Kankainen , M & Mustjoki , S 2021 , ' Mutational landscape of chronic myeloid leukemia : more than a single oncogene leukemia ' , Leukemia & lymphoma , vol. 62 , no. 9 , pp. 2064-2078 . https://doi.org/10.1080/10428194.2021.1894652

Title: Mutational landscape of chronic myeloid leukemia : more than a single oncogene leukemia
Author: Adnan-Awad, Shady; Kankainen, Matti; Mustjoki, Satu
Contributor organization: TRIMM - Translational Immunology Research Program
Department of Clinical Chemistry and Hematology
Hematologian yksikkö
University of Helsinki
HUSLAB
Research Programs Unit
Helsinki University Hospital Area
HUS Comprehensive Cancer Center
Department of Oncology
Digital Precision Cancer Medicine (iCAN)
Date: 2021-07-29
Language: eng
Number of pages: 15
Belongs to series: Leukemia & lymphoma
ISSN: 1042-8194
DOI: https://doi.org/10.1080/10428194.2021.1894652
URI: http://hdl.handle.net/10138/340395
Abstract: The BCR-ABL1 fusion gene, which causes aberrant kinase activity and uncontrolled cell proliferation, is the hallmark of chronic myeloid leukemia (CML). The development of tyrosine kinase inhibitors (TKI) that target the BCR-ABL oncoprotein has led to dramatic improvement in CML management. However, some challenges remain to be addressed in the TKI era, including patient stratification and the selection of frontline TKIs and CML progression. Additionally, with the emerging goal of treatment-free remission (TFR) in CML management, biomarkers that predict the outcomes of stopping TKI remain to be identified. Notably, recent reports have revealed the power of genome screening in understanding the role of genome aberrations other than BCR-ABL1 in CML pathogenesis. These studies have discovered the presence of disease-phase specific mutations and linked certain mutations to inferior responses to TKI treatment and CML progression. A personalized approach that incorporates genetic data in tailoring treatment strategies has been successfully implemented in acute leukemia, and it represents a promising approach for the management of high-risk CML patients. In this article, we will review current knowledge about the mutational profile in different phases of CML as well as patterns of mutational dynamics in patients having different outcomes. We highlight the effects of somatic mutations involving certain genes (e.g. epigenetic modifiers) on the outcomes of TKI treatment. We also discuss the potential value of incorporating genetic data in treatment decisions and the routine care of CML patients as a future direction for optimizing CML management.
Subject: Chronic myeloid leukemia
blast phase
somatic mutations
risk stratification
personalized medicine
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Mutational_land ... ngle_oncogene_leukemia.pdf 2.163Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record